Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma

Abstract excerpt

UNLABELLED: The majority of patients with melanoma harbor mutations in the BRAF oncogene, thus making it a clinically relevant target. However, response to mutant BRAF inhibitors (BRAFi) is relatively short-lived with progression-free survival of only 6 to 7 months. Previously, we reported high expression of ribonucleotide reductase M2 (RRM2), which is rate-limiting for de novo dNTP synthesis, as a poor...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Melanoma and MAPK Pathways
• Share to PARP inhibition in cancer therapy